Focus: DiscGenics is a private biotechnology company focused on spinal stem cell therapies for degenerative disc disease and other musculoskeletal conditions. Founded in 2008 and based in Salt Lake City, the company is advancing cell therapy solutions in an underserved orthopedic market.
Profile data last refreshed 13h ago · AI intelligence enriched 2w ago
Stable — net -2 jobs in 30d
0 added, 2 removed. Backfill posture.
Best suited for early-stage biotech enthusiasts willing to accept private-company financial uncertainty in exchange for deep involvement in pioneering cell therapy development.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for DiscGenics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from DiscGenics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Degenerative Disc Disease Pipeline 2026: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Mesoblast, DiscGenics, Biosplice Therapeutics, BIOPHARM - StreetInsider
Degenerative Disc Disease Pipeline 2026: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Mesoblast, DiscGenics, Biosplice Therapeutics, BIOPHARM StreetInsider
Chronic Pain Market Poised for Growth at a CAGR of 5% During the Forecast Period (2026-2036), as Rising Patient Burden and Novel Treatment Approaches are Creating New Opportunities | DelveInsight - PR Newswire UK
Chronic Pain Market Poised for Growth at a CAGR of 5% During the Forecast Period (2026-2036), as Rising Patient Burden and Novel Treatment Approaches are Creating New Opportunities | DelveInsight PR Newswire UK
DiscGenics Appoints Healthcare Entrepreneur and Medtech Executive Chad Falciani to Board of Directors - ACCESS Newswire
DiscGenics Appoints Healthcare Entrepreneur and Medtech Executive Chad Falciani to Board of Directors ACCESS Newswire
Degenerative Disc Disease Market Statistics Expected to Experience Major Growth by 2036, According to DelveInsight | Mesoblast, DiscGenics, Biosplice Therapeutics, BIOPHARM GmbH, Yuhan, Histogen - barchart.com
Degenerative Disc Disease Market Statistics Expected to Experience Major Growth by 2036, According to DelveInsight | Mesoblast, DiscGenics, Biosplice Therapeutics, BIOPHARM GmbH, Yuhan, Histogen barchart.com
Degenerative Disc Disease Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Mesoblast, DiscGenics, Biosplice Therapeutics, BIOPHARM GmbH, Yuhan - Barchart.com
Degenerative Disc Disease Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Mesoblast, DiscGenics, Biosplice Therapeutics, BIOPHARM GmbH, Yuhan Barchart.com
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 9 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo